STOCK TITAN

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, has announced its participation in three major virtual investor conferences in April 2025:

  • H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference on April 2, 2025, featuring a fireside chat at 9:30 am ET
  • 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, with a fireside chat scheduled for 8:00 am ET
  • Stifel's 2025 Virtual Targeted Oncology Forum on April 9, 2025, including a fireside chat at 12:00 pm ET

All events will include fireside chats and one-on-one meetings. Live webcasts will be available on Compugen's website investor relations page, with replays accessible after the events.

Compugen (Nasdaq: CGEN), un'azienda di immunoterapia oncologica in fase clinica, ha annunciato la sua partecipazione a tre importanti conferenze virtuali per investitori nell'aprile 2025:

  • 2ª Conferenza Annuale sulla Scoperta e Sviluppo di Farmaci Basata su AI di H.C. Wainwright il 2 aprile 2025, con un incontro informale alle 9:30 ora ET
  • 24ª Conferenza Virtuale sulla Salute di Needham il 7 aprile 2025, con un incontro informale programmato per le 8:00 ora ET
  • Forum Virtuale di Oncologia Mirata 2025 di Stifel il 9 aprile 2025, che include un incontro informale alle 12:00 ora ET

Tutti gli eventi includeranno incontri informali e riunioni individuali. Le trasmissioni in diretta saranno disponibili sulla pagina delle relazioni con gli investitori del sito web di Compugen, con le registrazioni accessibili dopo gli eventi.

Compugen (Nasdaq: CGEN), una empresa de inmunoterapia contra el cáncer en etapa clínica, ha anunciado su participación en tres importantes conferencias virtuales para inversores en abril de 2025:

  • 2ª Conferencia Anual sobre Descubrimiento y Desarrollo de Medicamentos Basada en IA de H.C. Wainwright el 2 de abril de 2025, con una charla informal a las 9:30 am ET
  • 24ª Conferencia Virtual de Salud de Needham el 7 de abril de 2025, con una charla informal programada para las 8:00 am ET
  • Foro Virtual de Oncología Dirigida 2025 de Stifel el 9 de abril de 2025, que incluye una charla informal a las 12:00 pm ET

Todos los eventos incluirán charlas informales y reuniones uno a uno. Las transmisiones en vivo estarán disponibles en la página de relaciones con inversores del sitio web de Compugen, con repeticiones accesibles después de los eventos.

Compugen (Nasdaq: CGEN), 임상 단계의 암 면역 치료 회사가 2025년 4월에 열리는 세 가지 주요 가상 투자자 회의에 참여한다고 발표했습니다:

  • H.C. Wainwright 제2회 연례 AI 기반 약물 발견 및 개발 회의가 2025년 4월 2일 오전 9:30 ET에 진행됩니다.
  • 제24회 Needham 가상 헬스케어 회의가 2025년 4월 7일 오전 8:00 ET에 예정되어 있습니다.
  • Stifel의 2025년 가상 표적 종양학 포럼이 2025년 4월 9일 오후 12:00 ET에 진행됩니다.

모든 이벤트에는 비공식 대화와 일대일 회의가 포함됩니다. 라이브 웹캐스트는 Compugen의 투자자 관계 페이지에서 제공되며, 이벤트 후에는 다시 볼 수 있습니다.

Compugen (Nasdaq: CGEN), une entreprise d'immunothérapie contre le cancer en phase clinique, a annoncé sa participation à trois grandes conférences virtuelles pour investisseurs en avril 2025 :

  • 2ème Conférence Annuelle sur la Découverte et le Développement de Médicaments Basée sur l'IA de H.C. Wainwright le 2 avril 2025, avec une discussion informelle à 9h30 ET
  • 24ème Conférence Virtuelle sur la Santé de Needham le 7 avril 2025, avec une discussion informelle prévue à 8h00 ET
  • Forum Virtuel sur l'Oncologie Ciblée 2025 de Stifel le 9 avril 2025, incluant une discussion informelle à 12h00 ET

Tous les événements comprendront des discussions informelles et des réunions individuelles. Les webcasts en direct seront disponibles sur la page des relations investisseurs de Compugen, avec des rediffusions accessibles après les événements.

Compugen (Nasdaq: CGEN), ein Unternehmen für klinische Krebsimmuntherapie, hat seine Teilnahme an drei wichtigen virtuellen Investorenkonferenzen im April 2025 angekündigt:

  • 2. Jährliche AI-basierte Arzneimittelentdeckungs- und Entwicklungs-Konferenz von H.C. Wainwright am 2. April 2025, mit einem informellen Gespräch um 9:30 Uhr ET
  • 24. Jährliche virtuelle Gesundheitskonferenz von Needham am 7. April 2025, mit einem informellen Gespräch um 8:00 Uhr ET
  • Stifels 2025 Virtuelles Forum für gezielte Onkologie am 9. April 2025, einschließlich eines informellen Gesprächs um 12:00 Uhr ET

Alle Veranstaltungen umfassen informelle Gespräche und Einzelgespräche. Live-Webcasts sind auf der Investor Relations-Seite von Compugen verfügbar, mit Aufzeichnungen, die nach den Veranstaltungen zugänglich sind.

Positive
  • None.
Negative
  • None.

HOLON, Israel, March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025:

H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference
Date: Wednesday, April 2, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 9:30 am ET

24th Annual Needham Virtual Healthcare Conference
Date: Monday, April 7, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 8:00 am ET

Stifel's 2025 Virtual Targeted Oncology Forum
Date: Wednesday, April 9, 2025
Format: Fireside chat and 1x1 meetings
Fireside chat time: 12:00 pm ET

Live webcasts of the fireside chats will be available on the events page of the Investor Relations section of Compugen's website at www.cgen.com. Replays will be available following the live events.

About Compugen 
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071  

Cision View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-multiple-virtual-investor-conferences-in-april-2025-302411894.html

SOURCE Compugen Ltd.

FAQ

Which investor conferences will Compugen (CGEN) attend in April 2025?

Compugen will participate in three conferences: H.C. Wainwright AI Based Drug Discovery Conference (April 2), Needham Virtual Healthcare Conference (April 7), and Stifel's Virtual Targeted Oncology Forum (April 9).

What is the schedule for Compugen's (CGEN) fireside chats in April 2025 conferences?

Fireside chats are scheduled for 9:30 am ET on April 2, 8:00 am ET on April 7, and 12:00 pm ET on April 9, 2025.

How can investors access Compugen's (CGEN) April 2025 conference presentations?

Live webcasts will be available on Compugen's website investor relations events page at www.cgen.com, with replays available after the events.

What types of meetings will Compugen (CGEN) offer during the April 2025 conferences?

Compugen will offer both fireside chat presentations and one-on-one meeting opportunities at all three virtual conferences.
Compugen

NASDAQ:CGEN

CGEN Rankings

CGEN Latest News

CGEN Stock Data

132.32M
91.62M
2.03%
14.32%
1.77%
Biotechnology
Healthcare
Link
Israel
Holon